Compare Charles River Laboratories Intl. Inc (CRL) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Charles River Laboratories Intl. Inc trades at $283 (market cap $13.58B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $34.05. Which is the better fit depends on your goals.
| CRL | FNGU | |
|---|---|---|
Market Cap | $13.58B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $284.37 | $36.15 |
52-Week Low | $145.57 | $13.73 |
Enterprise Value | $16.41B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $281.27, near its 52-week high, with a slight 0.26% decline. The stock shows bullish technical signals, including strong moving averages, despite overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $3.02 versus $2.74 expected, and the company raised full-year guidance, reflecting improved biotech demand. However, fundamentals reveal challenges, with a negative net income margin of -5.96% and elevated P/E ratio of 684.85, indicating high valuation relative to profitability.
Outlook: CRL benefits from positive analyst sentiment (72% buy ratings) and institutional accumulation, but risks include profitability pressures, high debt, and reliance on biotech sector health. The consensus price target of $277.29 suggests limited upside, urging caution despite operational improvements.
FNGU, a 3X leveraged ETN tracking FANG+ stocks, trades at $32.19, down 1.62% on the day. Technical indicators show a bullish trend with moving averages supporting upside, but RSI levels above 70 suggest overbought conditions. Recent news highlights extreme volatility, with a 16% single-day loss reported on June 5, 2026 (24/7 Wall Street).
The outlook remains high-risk due to leverage amplifying moves; potential for rapid gains exists if tech rallies, but structural decay and volatility erosion pose severe risks. Investors must understand the product's design, as hidden costs beyond the 0.95% fee can significantly impact returns over time.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
